Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Simcere Pharmaceutical, a manufacturer and supplier of generic pharmaceuticals in China, has acquired 37.5% stake in Jiangsu Yanshen from existing shareholders for a total cash consideration of approximately RMB195.5 million.
Subscribe to our email newsletter
In addition, Jiangsu Yanshen has received a new medicine certificate from the PRC State Food and Drug Administration (SFDA) for its freeze-dried human use rabies vaccine (vero cell).
The clinical trail of purified hepatitis A inactivated vaccine (vero cell) has already been completed.
However, SFDA’s approval for the purified hepatitis A inactivated vaccine (vero cell) and GMP certification for the associated new manufacturing facility are pending.
Jinsheng Ren, Chairman and CEO of Simcere Pharmaceutical Group, said: we are delighted to enter this new market through our investment in Jiangsu Yanshen. This is another significant development for Simcere in the biopharmaceutical area, following our recent investment in Shanghai Celgen Bio-Pharmaceutical Co., Ltd.